6-K - PRF Technologies Ltd. (0001801834) (Filer)

6-K - PRF Technologies Ltd. (0001801834) (Filer)

6-K - PRF Technologies Ltd. (0001801834) (Filer)

6-K - PAINREFORM LTD. (0001801834) (Filer)

6-K - PAINREFORM LTD. (0001801834) (Filer)

6-K - PAINREFORM LTD. (0001801834) (Filer)

6-K - PAINREFORM LTD. (0001801834) (Filer)

6-K - PAINREFORM LTD. (0001801834) (Filer)

6-K - PAINREFORM LTD. (0001801834) (Filer)

6-K - PAINREFORM LTD. (0001801834) (Filer)

TEL AVIV, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") (formerly "PainReform") today announced that its DeepSolar business unit has entered into a solar analytics services agreement with a subsidiary of EDF Group (Electricite' De France, France's Electric Company, one of the largest international energy companies), a global leader in renewable energy, relating to an operational, utility-scale solar power plant in Israel. This engagement represents the next phase of Deep Solar's previously announced strategy and a new commercial revenue opportunity—an important milestone following the recent launch of Smart TDD. Pursuant to the agre

TEL AVIV, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PRF Technologies (NASDAQ:PRFX) ("PRF" or the "Company"), through its DeepSolar™ AI-driven solar analytics business unit, today announced the signing of a software-as-a-service (SaaS) agreement with Shikun & Binui Energy for the deployment of DeepSolar at the 71 megawatt (MW) Satu Mare photovoltaic site in Romania. The Satu Mare project is a utility-scale solar plant owned and operated by Shikun & Binui Energy. Under the agreement, DeepSolar will provide continuous analytics and performance monitoring designed to enhance operational visibility, support proactive asset management, and enable data-driven decision-making throughout the proje

Patent filing follows acceptance into the NVIDIA Connect Program  Proprietary software targets weather forecast-driven revenue optimization, reduced penalty risk, and improved market performance for utility-scale solar assets TEL AVIV, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") (formerly "PainReform") today announced that it has filed a patent application covering proprietary methods for solar plant–level micro-climate modeling designed to significantly improve the accuracy of solar energy production forecasts in competitive electric utility markets. The patent follows acceptance into the prestigious NVIDIA Connect Program and

TEL AVIV, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") (formerly "PainReform") today announced its corporate name change to PRF Technologies Ltd. following shareholder approval at the Company's Annual General Meeting held on Tuesday, January 6, 2026. The Company's Nasdaq ticker symbol will remain PRFX. The approved name change is intended to reflect the Company's evolution into a diversified innovation platform spanning specialty pharmaceuticals, advanced drug-delivery technologies, and AI-driven renewable-energy analytics, marking a strategic shift beyond its original single-product focus. Over the past 18 months, PRF has signifi

TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, together with its majority-owned subsidiary LayerBio, Inc., today announced safety data supporting the continued development of OcuRing™-K drop-less, sustained-release ocular drug delivery platform for use in cataract surgery. The development program included a series of preclinical rabbit studies evaluating ocular tolerability, biocompatibility, and tissue response, as well as a Phase I clinical study in patients undergoing cataract surgery. Collectively, these studies dem

TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) today announced that its DeepSolar business unit has launched Smart TDD, an advanced solar Technical Due Diligence ("TDD") service designed to provide faster, more accurate, and more comprehensive assessments of solar asset performance and risk. The newly enhanced service expands DeepSolar's audit capabilities to support independent power producers (IPPs), infrastructure funds, operators, lenders, and insurers at every major lifecycle milestone of a solar asset. Solar continues to experience historic global growth, with more than $500 billion invested in 2024 and over $60 billion in solar assets changing han

AI-driven monitoring and analytics solutions addressing the growing demand for energy efficiency in large-scale solar and critical infrastructure projects across the Middle East. TEL AVIV, Israel, Dec. 30, 2025 /PRNewswire/ -- BladeRanger (TASE: BLRN), a provider of drone-based inspection, maintenance, and AI-driven analytics solutions for green energy and critical infrastructure, today announced its participation in Abu Dhabi Sustainability Week (ADSW), a leading global platform dedicated to sustainability, clean energy, and climate-related innovation. At the conference, BladeRanger will highlight its flagship platforms, including Solar Drone and their cooperation with DeepSolar platform o

TEL AVIV, Israel, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) today announced that its pharmaceutical division has completed an R&D assessment of LayerBio's proprietary drop-less, sustained-release ocular drug-delivery platform. The assessment confirmed that its sustained release, polymer matrix platform can incorporate a variety of drug entities, reinforcing its long-term potential to provide greatly improved pharmacological efficiency and simplify postoperative care for cataract patients by reducing or eliminating the need for medicated eye drops – the DROP-LESS advantage. The matrix platform successfully incorporated corticosteroids and NSAIDs—two major therapeutic

TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) today announced, through its pharmaceutical division, the commencement of its development plan for OcuRing™-K, LayerBio's patented, drop-less, intraoperatively administered sustained-release ocular therapy designed to deliver controlled, site-specific release of ketorolac following cataract surgery. Following the closing of PainReform's majority investment in LayerBio and the integration of OcuRing-K into PainReform's development portfolio, the Company conducted a methodical internal assessment with LayerBio's management team to define development priorities and establish a clear path for advancing the progra

TEL AVIV, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) today announced that DeepSolar, its solar energy business unit developing next-generation AI analytics, has advanced the development of its proprietary automated reporting engine, designed to transform how solar-asset performance is analyzed, understood, and communicated. The automated reporting engine reduces manual effort and produces tailored reports according to the customers' needs. Performance reports are essential tools for executive management, investors, and asset owners to assess a plant's operational and financial performance, identify the root causes of output variations, and evaluate return on

HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.  Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri

HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing

SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)

SC 13D - PAINREFORM LTD. (0001801834) (Subject)

SC 13G - PAINREFORM LTD. (0001801834) (Subject)

SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

SC 13G - PAINREFORM LTD. (0001801834) (Subject)

SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)